Multiomics Market: Platforms, Products and Partnerships Driving Research Demand

The multiomics market spans instruments, consumables, software and services that let researchers study genes, proteins, metabolites and cells together. According to Polaris Market Research, the market was valued at USD 3.20 billion in 2025 and is projected to reach USD 11.53 billion by 2034, with North America the largest market in 2025. This article reviews where demand is concentrated and which companies are active.

Products and Services Anchor Demand

The Product & Service segment held the largest revenue share of 76.0% in 2025, driven by strong demand for instruments, consumables and multiomics products. Automation is part of this picture: in January 2025, BD and Hamilton collaborated to standardize single-cell experiments using robotics, with the aim of greater standardization and fewer human errors.

Multiomics software is gaining importance because these studies generate large volumes of data. In June 2025, SCIEX offered its OneOmics Suite, a cloud-based platform for processing complex datasets across proteomic, metabolomic, genomic and multiomic applications. Polaris notes that it supports data management, quantification, visualization, statistical analysis and pathway analysis. Wider multiomics software adoption depends on resolving data integration complexity and the shortage of bioinformatics professionals.

Genomics and Sequencing Technologies

Genomics was the largest platform by revenue in 2025, with a 32.0% share, supported by advances in sequencing technologies and declining sequencing costs. In May 2025, Illumina released DRAGEN v4.4, which strengthens clinical oncology and multiomics research with enhanced variant-detection algorithms and faster whole-genome processing. In October 2025, Biomodal launched a Certified Service Provider program for its duet multiomics 5-base and 6-base solutions, which provide genetic and epigenetic information from a single low-input DNA sample. Growing demand for advanced sequencing technologies and data analysis tools is also increasing the use of transcriptomics in pharmaceutical, biotechnology and academic research.

Proteomics Adds Functional Depth

Proteomics focuses on proteins, which perform most functions inside cells. It is used for protein identification, functional biology studies, biomarker discovery, drug response monitoring and disease pathway analysis. Protein-level data provide information beyond genome data alone, which is why proteomics is described as an important opportunity within multiomics research.

Large-scale programs show the scale of activity. In January 2025, Thermo Fisher Scientific partnered with the UK Biobank on a large-scale human proteomics study that uses the Olink Explore platform to analyze more than 5,400 proteins from 600,000 samples.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/multiomics-market 

Metabolomics Platforms Show the Fastest Growth

Among platforms, metabolomics is projected to grow at the highest CAGR of 14.8% from 2026 to 2034, driven by technological advances and expanding use in personalized medicine and drug discovery. Demand for advanced metabolomics platforms, analytical tools and data analysis solutions is rising across pharmaceutical, biotechnology and academic research. In May 2025, Bruker launched the timsMetabo mass spectrometer for 4D metabolomics and 4D lipidomics. Such launches show how vendors are broadening their metabolomics platforms portfolios.

Precision Medicine as the Common Thread

Multiomics gives a better understanding of each patient's condition, helping select more suitable treatments, which is why it is central to precision medicine. Public research funding supports this direction: in June 2026, the National Institutes of Health's All of Us Research Program added multiomics data from nearly 10,000 participants with proteomics data and nearly 9,000 with RNA sequencing data, bringing the program to more than 747,000 participants and supporting research on human health and precision medicine. Europe is expected to grow at the fastest regional CAGR of 14.9% during 2026–2034, helped by government support for genomics research.

Competitive Landscape

Polaris names Thermo Fisher Scientific, Illumina, BD, Beckman Coulter Life Sciences, Revvity, Shimadzu Corporation, Bruker, QIAGEN, Agilent Technologies, BGI Genomics, 10x Genomics, Bio-Rad Laboratories, Mission Bio, Standard BioTools and Takara Bio among the leading companies. Established players build integrated ecosystems across genomics, transcriptomics, proteomics, metabolomics and related workflows, while specialist players concentrate on single-cell, spatial and advanced analytical workflows. High technology costs remain a restraint, but Polaris expects multiomics to play an increasing role in healthcare and life sciences.

Conclusion

The Multiomics Market is expected to witness significant growth, driven by increasing demand for precision medicine and advancements in genomic and molecular research. The integration of genomics, proteomics, metabolomics, and transcriptomics is improving the understanding of complex biological systems. Growing investments in biotechnology research and drug discovery are supporting market expansion. Additionally, advancements in artificial intelligence and bioinformatics are enhancing multiomics data analysis and interpretation. However, high implementation costs and data integration challenges may limit widespread adoption. Continued technological innovation and expanding applications in personalized healthcare are expected to create substantial growth opportunities.

More Trending Latest Reports By Polaris Market Research:

Bio-Based Epoxy Resins Market

Ethyleneamines Market

Laparoscopic Retrieval Bag Market

T4 DNA Ligase Market

Ethyleneamines Market

Muscle Stimulator Market

Metalworking Fluids Market

Increasing Demand for Medical Holography Products in the research field Propel Market Growth

Bus Market